Protocol summary
-
Study aim
-
The aim of this study is to determine the effects of vitamin D supplementation on metabolic profiles in patients of polycystic ovary syndrome (PCOS).
-
Design
-
Study design: Parallel double-blind (both patients and researchers) clinical trial. Randomization will be done by the use of computer-generated random numbers.
-
Settings and conduct
-
Population and sample size: Among patients with PCOS referred to Kosar Clinic affiliated to Arak University of Medical Sciences, 70 patients will be selected according to inclusion and eclusion criteria.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with phenotype B of PCOS according to Rotterdam criteria and aged 18 to 40 years. Exclusion criteria: Pregnant women, women with endocrine diseases including diabetes or impaired glucose tolerance
-
Intervention groups
-
Intervention: Patients will be assigned into two groups to receive vitamin D with dosage of 50000 IU (n=35) or placebo (n=35) every two weeks. Vitamin D supplements and placebos capsules are similar in shape and size.
-
Main outcome variables
-
Outcomes: Markers of insulin metabolism and hormonal profiles (primary outcomes) and lipid profiles, biomarkers of inflammation and oxidative stress (secondary outcome) will be quantified at study baseline and end-of-trial.
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT201606115623N82
Registration date:
2016-07-01, 1395/04/11
Registration timing:
retrospective
Last update:
2019-09-23, 1398/07/01
Update count:
1
-
Registration date
-
2016-07-01, 1395/04/11
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Expected recruitment start date
-
2016-04-24, 1395/02/05
-
Expected recruitment end date
-
2016-05-04, 1395/02/15
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Clinical trial of the effect of vitamin D supplementation compared with the placebo on metabolic profiles in women with polycystic ovary syndrome
-
Public title
-
Effect of supplementation in treatment of women with polycystic ovary syndrome
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patients with phenotype B of PCOS according to Rotterdam criteria
Aged between18 to 40 years old
Exclusion criteria:
Pregnant women
Women with endocrine diseases including diabetes or impaired glucose tolerance
-
Age
-
From 18 years old to 40 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
70
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
At study baseline and after stratification for pre-intervention BMI and age, subjects will be randomly divided into two groups to take vitamin D supplementation (n=35) or placebo (n=35). Randomization will be done by the use of computer-generated random numbers.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Participants, investigators or the assessors of the outcomes are unaware of the study groups.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2016-04-23, 1395/02/04
-
Ethics committee reference number
-
IR.ARAKMU.REC.1395.41
Health conditions studied
1
-
Description of health condition studied
-
Polycystic ovary syndrome
-
ICD-10 code
-
E28.2
-
ICD-10 code description
-
Polycystic ovarian syndrome
Primary outcomes
1
-
Description
-
Insulin
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
2
-
Description
-
Insulin resistance
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Questionnaire
3
-
Description
-
Total testosterone
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
4
-
Description
-
SHBG
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
5
-
Description
-
Free testosterone
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
Secondary outcomes
1
-
Description
-
Total antioxidant
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
2
-
Description
-
Cholesterol
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Enzymatic kit
3
-
Description
-
HDL-cholesterol
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Enzymatic kit
4
-
Description
-
hs-CRP
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
5
-
Description
-
Nitric oxide
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
6
-
Description
-
Triglycerides
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Enzymatic kit
7
-
Description
-
Glutathione
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Enzymatic kit
8
-
Description
-
Malondialdehyde
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Enzymatic kit
9
-
Description
-
VLDL
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Enzymatic kit
10
-
Description
-
Hirsutism
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Clinical observation
Intervention groups
1
-
Description
-
Intervention group: Vitamin D supplements, 50000 IU, every two weeks, for 12 weeks orally.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Placebo capsule, every two weeks for 12 weeks orally.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available